Cart 0
Targeted Therapy for Solid Tumors & Hematologic Malignancies
Click to zoom

Share this book

Targeted Therapy for Solid Tumors & Hematologic Malignancies

Book Details

Format Hardback or Cased Book
ISBN-10 1617618543
ISBN-13 9781617618543
Publisher Nova Science Publishers Inc
Imprint Nova Science Publishers Inc
Country of Manufacture US
Country of Publication GB
Publication Date Jun 10th, 2011
Print length 324 Pages
Weight 796 grams
Dimensions 26.50 x 18.90 x 2.40 cms
Product Classification: Oncology
Ksh 52,750.00
Not available 0 in stock

Delivery Location

Delivery fee: Select location

Secure
Quality
Fast
Endocrine malignancies are rare tumours that are derived from endocrine cells located throughout the body. They encompass a heterogeneous group of malignancies, derived from different endocrine and neuroendocrine cells and have different clinically. The majority of endocrine neoplasms are benign, where the potential for invasion or metastasis is very low. Nevertheless, there is a group of endocrine neoplasms with malignant potential, and thus come under the management of medical oncology, often requiring systemic therapy. These include neuroendocrine tumours, anaplastic and medullary thyroid carcinomas, pheochromocytomas or paragangliomas, and adrenocortical carcinomas. While surgery continues to play a seminal role, the management of advanced endocrine neoplasia is more complex due to their rarity and heterogeneity. This book discusses the use of targeted therapy in the treatment of solid tumours and hematologic malignancies.

Get Targeted Therapy for Solid Tumors & Hematologic Malignancies by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Nova Science Publishers Inc and it has pages.

Mind, Body, & Spirit

Shopping Cart

Africa largest book store

Sub Total:
Ebooks

Digital Library
Coming Soon

Our digital collection is currently being curated to ensure the best possible reading experience on Werezi. We'll be launching our Ebooks platform shortly.